Skip to main content

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Regeneron Pharmaceuticals



) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 0.5%. By the end of trading, Regeneron Pharmaceuticals fell $9.65 (-3.2%) to $293.43 on average volume. Throughout the day, 1,016,654 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 1,205,800 shares. The stock ranged in price between $291.36-$306.70 after having opened the day at $305.77 as compared to the previous trading day's close of $303.08. Other companies within the Drugs industry that declined today were:




), down 9.9%,

China Pharma



), down 8.8%,

Actinium Pharmaceuticals



), down 8.8% and

Oramed Pharmaceuticals



), down 8.6%.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $30.5 billion and is part of the health care sector. Shares are up 10.1% year to date as of the close of trading on Wednesday. Currently there are 8 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates

Regeneron Pharmaceuticals

as a


. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and feeble growth in the company's earnings per share.

On the positive front,

Synergy Pharmaceuticals



), up 10.9%,




), up 9.0%,




), up 8.1% and

Array BioPharma



), up 7.6% , were all gainers within the drugs industry with

Alexion Pharmaceuticals



) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech




STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.